Glenmark Pharmaceuticals Limited waxay soo bandhigtay qiyaas cusub oo isku dhafan oo go'an (FDC) oo ah inhibitor DPP4 (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, oo leh Pioglitazone. Kani waa summada isku darka DPP4 iyo Glitazone ee keliya ee laga heli karo Hindiya ee loogu talagalay dadka waaweyn ee qaba Nooca 2 ee sonkorowga aan la xakameynin. Glenmark waxay soo saartay FDC-gan iyada oo hoos imanaysa magaca sumadda Zita Plus Pio, oo ka kooban Teneligliptin (20 mg) + Pioglitazone (15 mg), in la qaato hal mar maalintii.
Isagoo ka faalloonaya horumarka, Alok Malik, Ku-Xigeenka Kooxda & Madaxa, Qaababka Hindiya - Glenmark Pharmaceuticals, ayaa yiri, "Macaanku waa aag muhiim ah oo diiradda saaraya Glenmark; hormood u ah bixinta fursadaha daawaynta ugu dambaysay ee bukaannada macaanka ee Hindiya. Waxaan ku faraxsanahay inaan soo bandhigno sheeko-yaqaanka Zita Plus Pio, oo ah kii ugu horreeyay ee noociisa ah ee Hindiya; siinta daweyn heer caalami ah oo la awoodi karo oo la siinayo bukaannada waaweyn ee macaanka qaba."
Glenmark waa shirkaddii ugu horeysay ee Hindiya si ay u suuq geyso FDC-da cusub ee Teneligliptin + Pioglitazone, oo ay ansixisay DCGI (Maamulaha Guud ee Dawooyinka Hindiya). Isku darka qiyaasta go'an waxay faa'iido u yeelan doontaa bukaanada u baahan daawaynta Teneliglitptin iyo Pioglitazone (sida dawooyin gaar ah) si loo hagaajiyo xakamaynta glycemic yaraynta iska caabinta Insulin.
Nooca 2 ee sonkorowga ayaa caadi ahaan la kulma arrimo ku saabsan cilladda unugyada β iyo caabbinta insulin. Glenmark's FDC ee Teneligliptin + Pioglitazone ayaa leh waxtarka uu wax kaga qabanayo labadan cudur-siyeed ee ugu muhiimsan taasoo ka dhigaysa FDC mid waxtar u leh maaraynta nooca 2 ee sonkorowga aan la xakameynin. Isku darka Teneligliptin + Pioglitazone waxay bixin doontaa hab isku dheelitiran oo Teneligliptin ay si wanaagsan u wanaajin doonto dareenka unugyada β, Pioglitazone waxay si wax ku ool ah u yaraynaysaa iska caabbinta insulin.
Wax ku biirinta Glenmark ee daaweynta sonkorowga
Sannadkii 2015, Glenmark waxa ay wax ka beddeshay suuqa sonkorowga iyada oo soo saartay DPP4 inhibitorkeeda - Teneligliptin gudaha Hindiya, oo ay ku xigto FDC ee Teneligliptin + Metformin. Glenmark waxay leedahay dhaxal xooggan oo in ka badan afartan sano oo horumar iyo hal-abuurnimo ah. Iyada oo ku sii socota markii ugu horreysay ee dhaxalka Hindiya, waxay soo saartay FDC ee Teneligliptin + Remogliflozin sanadka 2021.
Hindiya waxaa loo yaqaanaa inay tahay caasimadda adduunka ee sonkorowga. Marka loo eego Xiriirka Caalamiga ah ee Sonkorowga (IDF), faafidda cudurka macaanka ee Hindiya waa ku dhawaad 74 milyan oo qaangaar ah, kaas oo la filayo inuu kordho 125 milyan (ku dhawaad 70% koror) 2045[i]. Kuwaas, 77% bukaannada ayaa qaba cudurka macaanka oo aan la xakameynin.